Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pamicogrel (Kanebo).

P Light1

  • 1Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Drive, Alberta, Canada. plight@acs.ucalgary.ca

Idrugs : the Investigational Drugs Journal
|August 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sitagliptin plus pantoprazole can restore but not maintain insulin independence after clinical islet transplantation: results of a pilot study.

Diabetic medicine : a journal of the British Diabetic Association·2016
Same author

Electromagnetically-induced transparency grid in acetylene-filled hollow-core PCF.

Optics express·2009
Same author

Nesiritide citrate (Scios).

IDrugs : the investigational drugs journal·2005
Same author

Azimilide (Procter & Gamble).

IDrugs : the investigational drugs journal·2005
Same author

Vancomycin-resistant enterococci colonization in patients at seven hemodialysis centers.

Kidney international·2001
Same author

A prospective study of vascular access infections at seven outpatient hemodialysis centers.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2001
Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010
Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010
Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010
Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010
Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010
Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010
See all related articles

Pamicogrel, a cyclooxygenase inhibitor, is being developed for chronic arterial occlusion and may help prevent and treat ischemic brain injury. Its anti-platelet properties are key to its therapeutic potential.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Cardiovascular Medicine

Background:

  • Pamicogrel is a cyclooxygenase inhibitor developed by Kanebo.
  • It exhibits significant platelet anti-aggregatory properties.
  • The drug is under development for chronic arterial occlusion.

Purpose of the Study:

  • To evaluate the potential of Pamicogrel in the prophylaxis and treatment of ischemic brain injury.
  • To explore its therapeutic applications beyond chronic arterial occlusion.

Main Methods:

  • The study likely involved assessing Pamicogrel's effects on platelet aggregation.
  • Further studies would investigate its efficacy in models of cerebral circulation disturbances.

Main Results:

Related Experiment Videos

  • Pamicogrel demonstrates potent platelet anti-aggregatory effects.
  • The drug shows promise for managing conditions like cerebral hemorrhage and infarction.

Conclusions:

  • Pamicogrel is a promising therapeutic agent for ischemic brain injury and chronic arterial occlusion.
  • Its mechanism involves inhibiting cyclooxygenase and reducing platelet aggregation.